1. Measured by its binding ability in a functional ELISA. Immobilized VEGF C-his at 2 μg/mL (100 μL/well) can bind VEGFR3 hFc, the EC50 of VEGFR3 hFc is 2-15 ng/mL. 2. Scatchard analysis showed the affinity constant (Kd) of recombinant human VEGF-C bound to recombinant human VEGFR3 was 1.4 nM. 3. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 0.1-0.5 μg/mL. 4. Captured VEGFR3/FLT4 Protein, Human on anti-Human IgG Fc via CM5 Chip can bind VEGF-C with an affinity constant of 31.82 pM as determined in a SPR assay (Routinely tested).

VEGFC Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 15.5 kDa and the accession number is P49767.

Human

HEK293 Cells

VRP,VEGF-C,vascular endothelial growth factor C,LMPH1D,Flt4-L

A DNA sequence encoding the mature form of human VEGFC (NP_005420.1) (Thr103-Arg227) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Thr 103

> 95 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Vascular endothelial growth factor C (VEGF-C) is a member of the VEGF family. Upon biosynthesis, VEGF-C protein is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF-C protein is a dimeric glycoprotein, as a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. VEGF-C may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis. VEGF-C protein is over-expressed in various human cancers including breast cancer and prostate cancer. VEGF-C/VEGFR-3 axis, through different signaling pathways, plays a critical role in cancer progression by regulating different cellular functions, such as invasion, proliferation, and resistance to chemotherapy. Thus, targeting the VEGF-C/VEGFR-3 axis may be therapeutically significant for certain types of tumors.